| ACTB | Actin Beta |
| AE | Adverse effect |
| AKT1 | RAC-alpha serine/threonine-protein kinase |
| ATRA | All-trans retinoic acid |
| BC | Breast cancer |
| BCC | Breast cancer cells |
| CTC | Circulating tumor cells |
| COL4A5 | Collagen type IV alpha 5 chain |
| CTNNA1 | Catenin alpha 1 |
| CTNNB1 | Catenin beta 1 |
| D | Day |
| ECM | Extracellular matrix |
| EGFR | Epidermal growth factor receptor |
| ERα | Estrogen receptor-alpha |
| ERβ1 | Estrogen receptor-beta1 |
| ERK1 | Extracellular signal-regulated kinase 1 |
| EVs | Extracellular vesicles |
| FAs | Fibroadenomas |
| FELs | Fibro-epithelial lesions |
| GRHL2 | Grainyhead-like 2 |
| Her-2 | Human epidermal growth factor receptor 2 |
| ITGB1 | Integrin-beta1 |
| MAPK14 | Mitogen-activated protein kinase 14; p38 |
| MCSs | Multicellular spheroids |
| NACT | Neoadjuvant chemotherapy |
| OHT | 4-hydroxytamoxifen |
| OS | Overall survival |
| PD | Progression of disease |
| PTs | Phyllodes tumors |
| PD-L1 | Programmed cell death ligand-1 |
| RPM | Random positioning machine |
| sTILs | Stromal tumor-infiltrating lymphocytes |
| TNBC | Triple-negative breast cancer |
| TUBB | Tubulin-beta |